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TauAnticholinergics, and drugs with anticholinergic properties, are widely and frequently prescribed, especially to
the elderly. It is well known that these drugs decrease cognitive function and increase the risk of dementia. Al-
though themechanism of anticholinergic drug-induced cognitive impairment has been assumed to be function-
ally reduced acetylcholine (ACh) neurotransmission, some data have indicated that anticholinergics might
enhance the pathology of Alzheimer's disease. In this study, we investigated the pathological effects of anticho-
linergics on neurodegeneration. We chronically administered two anticholinergics, trihexyphenidyl (TP) and
propiverine (PP) (the latter with less central anticholinergic action), to neurodegenerative tauopathy model
mice 2 to 10 months old. Furthermore, because the ACh nervous system regulates both central and peripheral
inﬂammation, we administered TP or PP to PS19mice inwhichwe had artiﬁcially induced inﬂammation by lipo-
polysaccharide injection. Tau pathology, synaptic loss, and neurodegeneration in the hippocampal region, aswell
as tau insolubility and phosphorylation, weremarkedly increased in TP-treatedmice andmildly increased in PP-
treated mice. Furthermore, immunohistochemical analysis revealed microglial proliferation and activation.
Moreover, anticholinergics increased interleukin-1β expression in both the spleen and brain of the tauopathy
model mice intraperitoneally injected with lipopolysaccharide to induce systemic inﬂammation. Interestingly,
these alterations were more strongly observed in TP-treated mice than in PP-treated mice, consistent with the
level of central anticholinergic action. Anticholinergic drugs not only impair cognitive function by decreased
ACh neurotransmission, but also accelerate neurodegeneration by suppressing an ACh-dependent anti-inﬂam-
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Anticholinergics are widely used for treating overactive bladder or
Parkinson's symptoms in elderly people. Moreover, many drugs com-
monly prescribed to elderly people (such as antiemetics, antispas-
modics, bronchodilators, anti-arrhythmic drugs, antihistamines) have
anticholinergic properties. It is well known that these drugs might in-
duce cognitive decline and increase the severity of dementia symptoms
(Ancelin et al., 2006; Moore and O'Keeffe, 1999; Tune et al., 1992). Sur-
prisingly, a large-scale cohort study of elderly individuals identiﬁedmild
cognitive impairment (MCI) in 80% of patients on anticholinergic thera-
pies, and concluded that this therapy imparts a 5-fold increased risk of
MCI (Ancelin et al., 2006). A 6-year observational study in an African-
American population indicated that 53% of the population used a possi-
ble anticholinergic and 11% used a deﬁnite anticholinergic; the numberof deﬁnite anticholinergics was associatedwith an increased risk of cog-
nitive impairment (Campbell et al., 2010a). Similarly, a 4-year follow-up
study in France indicated that 7.5% of the participants were taking anti-
cholinergics, and that the use of these drugs was associated with an in-
creased risk of cognitive decline and dementia, which remained
signiﬁcant after adjustment for the multiple possible codeterminants
of cognitive decline (Carriere et al., 2009). An observational study in
Germany showed that 37% of the participants used anticholinergics,
and that they had an increased risk of dementia (hazard ratio=2.081)
in an anticholinergic activity-dependent manner (Jessen et al., 2010).
Moreover, there are signiﬁcant associations reported between high
serum anticholinergic activity and poor mini-mental state examination
(MMSE) scores (Mulsant et al., 2003). One explanation of these observa-
tions is functional suppression of the cholinergic system,which is closely
related to cognitive function. An autopsy study, however, demonstrated
a larger amount of amyloid plaques and neuroﬁbrillary tangles in the
brains of Parkinson's disease (PD) patients treated with anticholinergics
than in PDpatients not treatedwith anticholinergics, suggesting that an-
ticholinergic therapy might potentially enhance or induce Alzheimer's
disease (AD) pathology and neurodegeneration (Perry et al., 2003).
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hexyphenidyl (Artane™, TP), which is preferentially used for the treat-
ment of PD in Japan, and propiverine (BUP-4™, PP), which is used for
the treatment of overactive bladder and has a lower central anticholin-
ergic action (Kobayashi et al., 2007; Oka et al., 2001; Suzuki et al., 2007),
were administered to the P301S tauopathy model mice (PS19 mice).
Moreover, to investigate the effects of these anticholinergics on system-
ic inﬂammation, we administered TP or PP to PS19 mice in which we
had artiﬁcially induced systemic inﬂammation by lipopolysaccharide
(LPS) injection.
Methods
Tau transgenic (PS19) mice and drug treatment
The generation of transgenic (Tg)mice carrying the human tau gene
with a P301S mutation has been previous described by our group
(Yoshiyama et al., 2007). Brieﬂy, a cDNA construct of human T34 iso-
form tau (1N4R) harboring the P301S mutation was cloned into the
MoPrP.Xho expression vector containing a mouse prion (MoPrP) pro-
moter (Borchelt et al., 1996) at the XhoI site. A 15-kbNotI fragment con-
taining T34 and the MoPrP promoter, together with its 39 untranslated
sequences, was used as the transgene to create tau Tg mice on a
B6C3H/F1 background. A stable Tg line (PS19) and non-Tg offspring
were identiﬁed by PCR analysis of tail genomic DNA.
TP and PP were mixed with powdered food (TP, 1.5 mg/100 g; PP,
5 mg/100 g) and administered to groups of 15 PS19 mice and six WT
mice at 2 months of age. The estimated doses per body weight per day
were 1.5 mg/kg TP and 50 mg/kg PP, respectively. Ten PS19 and six
WT mice were fed powdered food containing no drug, and served as
the non-treated control (nTC) group.
All experiments were approved by the Committee of Animal Care
and Control in Chiba East National Hospital.
Immunohistochemistry
Themethods of tissue preparation and immunohistochemical analy-
sis have been previously described (Yoshiyama et al., 2000, 2007). Brief-
ly, mice were deeply anesthetized and transcardially perfused with
15 ml of phosphate-buffered saline (PBS). The brains and spinal cordTable 1
Primary antibodies used in this study.
Antibody Immunogen Ho
17026 Total tau Rab
AT8 Peptides containing phospho-S202/T205 tau Mo
T1 aa 189–207 of non-phosphorylated tau Mo
AT180 Peptides containing phospho-T231/S235 tau Mo
pTau (Ser46) Peptides containing phospho-S46 tau Go
pTau (S422) Peptides containing phospho-S422 tau Rab
Syntaxin Synaptic vesicle containing fractions of
immunoprecipitated human brain homogenate
Mo
Iba1 C terminus of Iba1 Rab
IL-1β aa 117–269 of human IL-1β Rab
SAPK/JNK Human JNK2 Rab
Phospho
SAPK/JNK
Phosphopeptide surrounding Thr183/Tyr185 of human SAPK/JNK Rab
GSK-3β aa 345–420 of human GSK-3β Rab
Phospho-GSK-3β aa containing phosphorylated ser9 of human GSK-3β Go
cdk5 aa 1–291 of human cdk5 Mo
Phospho-cdk5 aa containing phosphorylated Ser159 of human cdk5 Go











CD11b Mouse CD11b (5C6) Rat
CD68 Mouse CD68 (FA11) Rat
IHC, immunohistochemistry; WB, Western blotting.were removed, immersion-ﬁxed for 24 h in 4% paraformaldehyde in
PBS, then stored in 15% sucrose–PBS at 4 °C until further use. The tissue
was sectionedwith a cryostat in 20-μm-thick sections, whichwere used
for immunohistochemical analysis. Streptavidin–biotin-peroxidase
(Vector Laboratories, CA), as well as double-labeling immunoﬂuores-
cence, was used for staining. The antibodies and their dilutions used
are listed in Table 1.
Tau insolubility and phosphorylation states
Proteins were extracted from brains using high-salt (0.75 M NaCl)
reassembly buffer (RAB) [0.1 M MES, 1 mM EGTA, 0.5 mM MgSO4,
0.02 MNaF, 1 mMPMSF, and protease inhibitor cocktail (protease inhib-
itor cocktail set I, Calbiochem®, Merck, Germany)] by centrifugation at
50,000×g for 40 min at 4 °C in a Beckman TL-100 ultracentrifuge. The
RAB-insoluble pellets were re-homogenized with 1 M sucrose in RAB
and centrifuged at 40,000×g for 20 min at 4 °C to removemyelin and as-
sociated lipids. The resulting pellets were dissolvedwith 1 ml/g tissue in
a radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, 150 mM
NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 5 mM EDTA; pH
8.0, and protease inhibitor cocktail) and centrifuged at 40,000×g for
20 min at 4 °C. The supernatants were used as RIPA-soluble samples,
while the RIPA-insoluble pellets were extracted with 70% FA to recover
highly insoluble protein.
Imaging and statistical analyses
Images were captured with a Nikon Eclipse 80i microscope and a
Nikon DXM 1200C digital camera, and analyzed using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD). The results were
expressed as the mean±SEM. Statistically signiﬁcant differences
were determined by analysis of variance using SPSS statistical soft-
ware (SPSS, Chicago, IL). Statistical signiﬁcance was set at Pb0.05.
Western blot analysis
Brainswere homogenized, and diluted to 2 ml/g tissuewith ice-cold
1% triton high salt RAB in the presence of protease inhibitor cocktail
(protease inhibitor cocktail set I, Calbiochem®, Merck, Germany), fol-
lowed by centrifugation at 50,000×g for 40 min at 4 °C in a Beckmanst Dilution for IHC Dilution for WB Source
bit ×1000 Ishihara et al., 1999
use ×1000 ×500 Inogenetics (Alpharetta, GA)
use ×500 Binder et al., 1985
use ×500 Inogenetics (Alpharetta, GA)
at ×1000 Santa Cruz Biotechnology (Santa Cruz, CA)
bit ×1000 Abcam (Cambridge, UK)
use ×500 ×1000 Santa Cruz Biotechnology (Santa Cruz, CA)
bit ×1000 Wako (Osaka, Japan)
bit ×100 Santa Cruz Biotechnology (Santa Cruz, CA)
bit ×1000 Cell Signaling (Beberly, MA)
bit ×1000 Cell Signaling (Beberly, MA)
bit ×200 Santa Cruz Biotechnology (Santa Cruz, CA)
at ×200 Santa Cruz Biotechnology (Santa Cruz, CA)
use ×200 Santa Cruz Biotechnology (Santa Cruz, CA)
at ×200 Santa Cruz Biotechnology (Santa Cruz, CA)
bit ×1000 Cell Signaling (Beberly, MA)
bit ×1000 Cell Signaling (Beberly, MA)
use ×1000 Cell Signaling (Beberly, MA)
×100 Serotec (Kidlington, UK)
×200 Serotec (Kidlington, UK)
331Y. Yoshiyama et al. / Neurobiology of Disease 45 (2012) 329–336TLX ultracentrifuge. Protein concentrations were determined using a
BCA protein assay kit (Pierce, Rockford, IL), and proteins were resolved
by SDS–PAGE, followed by Western blotting. Signals were detected by
enhanced chemiluminescence (GE Healthcare, WI) according to the
manufacturer's instructions. The antibodies and their dilutions used
are listed in Table 1.
Results
Tau pathology and neuronal degeneration are enhanced by anticholiner-
gics in PS19 mice
The Tgmouse expressing 4R1Nhuman tauwith P301Smutation (line
PS19) used in this study exhibits synaptic loss and microglial activation
beginning at 3 months of age, followed by abnormal tau accumulation
starting around 6 months of age. Neuronal loss and brain atrophy can
be observed at about 8 months (Yoshiyama et al., 2007). To investigate
the effects of anticholinergics on tau pathology, TP or PP was adminis-
tered to these mice from age 2 to 10 months. Brain sections were histo-
pathologically or immunohistochemically analyzed at 10 months of age.
Eight of 15 (53% survival rate) TP-treated PS19 mice, 11 of 15 (73% sur-
vival rate) PP-treated PS19 mice, and seven of 10 (70% survival rate)
nTC PS19 mice, and all six WT mice survived to 10 months of age.
To compare the tau pathology among the groups, brain sections
were immunostainedwithAT8, an antibody speciﬁc for phosphorylated
tau. Although the distribution of tau-positive neurons, which were
mainly located in the hippocampus, amygdala, and spinal cord, was
similar in each group, TP-treated PS19 mice showed much stronger
tau pathology in the CA1 (Fig. 1I) and CA3 (Fig. 1J) regions, compared
with nTC PS19mice (Figs. 1A, B). Moreover, PP-treatment caused inter-
mediate tau pathology phenotype (Figs. 1E, F). AT8 immunostaining
with Nissl counterstaining (Figs. 1C, G, K) showed a disintegrated lam-
inar structure of the pyramidal neurons in the CA3 region in PP (Fig. 1G)
and TP (Fig. 1K) treated PS19 mice, and a high and low frequency, re-
spectively, of morphologically abnormal neurons with pyknotic nuclei
in TP-treated and PP-treated mice. Interestingly, most of pyknotic neu-
rons exhibited no intraneuronal tau accumulation (Figs. 1C, G, K). Statis-
tical analysis of the AT8-positive neurons in the CA1 and CA3 regions
revealed a signiﬁcantly increased number of AT8-positive neurons,
compared with the number in nTC, in TP-treated mice in CA1
(Fig. 1M) and PP-treated mice in CA3 (Fig. 1N). Although the number
of AT8-positive neurons in the CA3 region in TP-treated mice was
lower than expected, this might have been because of the decreased
numbers of neurons following neuronal cell death upon abnormal tau
accumulation. Therefore, Nissl-stained sections were examined to de-
termine the number and shape of neurons remaining in the hippocam-
pus. Low-magniﬁcation images of the hippocampal regions (Figs. 1D, H,
L) revealed a severe selective neuronal loss in the CA3 region, as well as
hippocampal atrophy, in PS19 mice treated with TP (Fig. 1L, arrow-
heads). Statistical analysis of the remaining neurons in the CA3 regions
of each group demonstrated signiﬁcant neuronal loss with TP treated
mice, compared with nTC mice (Fig. 1N), despite a lack of signiﬁcant
neuronal loss in the CA1 region in any group (Fig. 1M). To assess synap-
tic degeneration, syntaxin immunoreactivitywasmeasured byWestern
blotting. A signiﬁcant reduction in syntaxin immunoreactivity was ob-
served in TP-treated PS19 mouse brains (Fig. 1O).
Tau insolubility and phosphorylation are increased by anticholinergics
Sincemore tau-positive neuronswere observed in TP- andPP-treated
PS19 mice, the mice were subsequently analyzed for soluble and insolu-
ble tau by sequential extraction of brain sampleswith three buffers of in-
creasing extraction strength, as previously described (Ishihara et al.,
1999). Tau solubility decreased in the order nTCsNPP-treatedNTP-treated
(Fig. 2A). In particular, a slowlymigrating band (Figs. 2A, C, arrow),which
was highly phosphorylated and speciﬁcally recognized by AT8 (Fig. 2C,arrow), was more intense in TP-treated than in the PP-treated mouse
brain samples in the FA fractions. Samples in the RAB fractions were
also hyperphosphorylated in TP-treated PS19 mice (AT180 and pS422 in
Fig. 3).
Tau kinases are activated in anticholinergics-treated PS19 mice
To assess tau kinase activities causing tau phosphorylation, activated
and inactivated forms of GSK3β, CDK5 and MAPKs were measured in
TP-treated, PP-treated and nTC PS19 mice, and WT mice by Western
blotting (Fig. 3). For all of these enzymes except GSK3β, the phosphor-
ylated (p-) form is the activated form; p-GSK3β is the inactivated form.
Activation status in TP-treated, PP-treated, and nTC PS19 mice was
compared. TP treatment clearly enhanced the activation of GSK3β,
CDK5, and ERK, but not p38 or JNK. PP treatment mildly increased
GSK3β and CDK5 activation. These results indicate that anticholinergics
enhanced tau phosphorylation by activating tau kinases.
Microglial activation is induced by anticholinergics
Microglial-mediated neuroinﬂammation plays an important role in
neurodegeneration in a number of neurodegenerative diseases includ-
ing tauopathies, in fact, PS19 mice showmicroglial activation preceding
tau pathology and neuronal loss (Yoshiyama et al., 2007).Moreover, our
recent research indicated that enhancing cholinergic activity with done-
pezil suppressed neuronal inﬂammation including microglial activation
(Yoshiyama et al., 2010). Thus, we speculated that anticholinergics
might enhance microglial activation. Microglia in the brains of TP- or
PP-treated aswell as nTC PS19micewere analyzed immunohistochemi-
cally using microglia-speciﬁc antibodies. Double-immunolabeling for
Iba1 and tau clearly demonstrated marked microglial activation in the
brains of TP-treated PS19 mice (Figs. 4G–I) compared with nTC PS19
mice (Figs. 4A–C). Higher magniﬁcation images revealed enlarged,
Iba1-positive microglia with thick processes in the CA3 region in TP-
treated PS19 mice (Fig. 4K), whereas a few, small microglia with thin
processes were observed in the WT mouse brain (Fig. 4J, insert). In the
CA1 region of TP-treated PS19mice, themicroglia were elongated paral-
lel to theneuronal processes (Fig. 4L). Immunohistochemistry of activat-
ed microglial markers, including CD11b (Figs. 4O–R) and CD68 (cys.
4S–V), demonstrated obvious microglial activation in TP-treated PS19
mice (Figs. 4Q, R, U, V). Interestingly, CD68-positive microglia were
prominent in the granular cell layer of the hippocampus, including the
CA3 (Fig. 4V) and CA1 (Fig. 4Q) regions. However, Iba1-positive
(Figs. 4G–I) and CD11b-positive (Figs. 4Q, R)microglia were almost uni-
formly distributed throughout the white matter and gray matter in the
hippocampus, suggesting that CD68-positive microglia might be patho-
logically activated and directly involved in the neurodegeneration.
Microglial activation was mainly observed in the hippocampus, amyg-
dala, entorhinal cortex, and brain stem, corresponding to regions
where the tau pathology was predominantly observed (data not
shown). Statistical analysis of the percentage of Iba1-positive areas in
the CA1 or CA3 clearly demonstrated that TP treatment enhancedmicro-
gliosis in each hippocampal region (Figs. 4M, N).
LPS-induced systemic and neuronal inﬂammation is accelerated by
anticholinergics
Our data suggested that neuroinﬂammation enhanced by anticholin-
ergicswas involved in the acceleration of tau pathology andneurodegen-
eration in PS19mice. Next, we assessed the effects of anticholinergics on
systemic and neuronal inﬂammations artiﬁcially induced by LPS-injec-
tion. Immunohistochemistry for IL-1β in the spleen showed enhanced
staining in TP-treated mice (Fig. 5A) compared with PP-treated mice
(Fig. 5B) and nTC mice (Fig. 5C). Similarly, neuroinﬂammation repre-
sented by immunohistochemical staining for IL-1β (Figs. 5D–F) and
Iba1 (Figs. 5G–I) demonstrated enhanced neuroinﬂammation in TP-
Fig. 1. Anticholinergics trihexyphenidyl and propiverine accelerate neurodegenerative process in a tauopathy mouse model (PS19). Brains from PS19 mice treated with trihexyphe-
nidyl (TP) (I–L) or propiverine (PP) (E–H), and non-treated control (nTC) (A–D) PS19 mice were stained with AT8 (an antibody to phosphorylated tau) (A–C, E–F, I–K). Immuno-
histochemical staining for AT8 counterstained with hematoxylin in the CA1 (A, E, I) and the CA3 (B, F, J) regions demonstrate that the proportion of AT8-positive pyramidal neurons
is slightly increased in PP-treated (E, F) and clearly increased in TP-treated PS19 mice (I, J), compared with nTC PS19 mice (A, B). Interestingly, the pyramidal neurons in TP- or PP-
treated PS19 mice are poorly stained with hematoxylin, compared with neurons in nTC. The number of neurons in the CA3 region of TP-treated PS19 mice is apparently decreased
(N). In contrast, although there are more AT8-postive neurons in the CA1 region in TP-treated PS19 mice, the number of neurons in is not obviously decreased (M). To conﬁrm the
neuronal loss, hippocampal sections are stained with Nissl staining (D, H, L). Low-magniﬁcation images indicate decreased afﬁnity for the stain in pyramidal neurons, especially in
the CA3 region (arrows); the reduction is moderate in PP-treated (H) and severe in TP-treated (L) PS19 mice. In PP-treated PS19 mice, some atrophic neurons with pyknotic nuclei
are scatteringly seen in neurons faintly stained with Nissl (G). In TP-treated PS19 mice, the number of neurons is decreased; they are pyknotic and their shape is indicative of at-
rophy (K). The alteration in shape and Nissl-stainability of neurons is not related to tau accumulation (C, G, K). Statistical analysis indicated that in the CA1 region, the number of
AT8-positive neurons was increased in TP-treated PS19 mice compared to nTC PS mice, although the total neuron number was unchanged (M); however, in the CA3 region, the
number of AT8-positive neurons was increased in PP-treated PS19 mice but not in TP-treated PS19 mice, and the ratio of AT-8 positive neurons to the total number of neurons
was increased both in TP-treated and PP-treated PS19 mice. The neuronal loss was signiﬁcant in TP-treated mice. To quantify the synaptic loss, signals of syntaxin in Western
blots was measured revealing a signiﬁcant reduction in TP-treated mice (O). *, pb0.05, to nTC. Scale bars, 10 μm (A–C, E–G, I–K); 100 μm (D, H, L).
332 Y. Yoshiyama et al. / Neurobiology of Disease 45 (2012) 329–336treatedmice (Figs. 5D, G). These results suggest that anticholinergics en-
hanced not only neuroinﬂammation but also systemic inﬂammation in-
duced by LPS injections. Meanwhile, only administration of PP or TP to
PS19 mice without LPS-injection did not show obvious enhancement in
IL-1β expression or microglial activation (data not shown).
Discussion
Our study provides evidence that anticholinergics enhance tau pa-
thology, neurodegeneration and neuroinﬂammation aswell as systemic
inﬂammation in the neurodegenerative tauopathy mouse model PS19.With increasing interest in the effects of lifestyle on the development
dementia, the relationship of dementia to the use of anticholinergics
has attracted attention. These drugs have been shown to increase cogni-
tive impairment and dementia (Campbell et al., 2010b; Carriere et al.,
2009; Jessen et al., 2010), but they are widely and frequently prescribed
to elderly people (7.5–50%) with no particular cautions. The cognitive
impairment and dementia caused by anticholinergics was previously
suspected to be due to functional disruption of acetylcholine (ACh) neu-
rotransmission; however, our results indicate that these drugs might
accelerate neurodegenerative processes other than disrupted neuro-
transmission. Interestingly, PP, which has less central anticholinergic
Fig. 2. Increased tau insolubility in the brain of PS19 mice treated by trihexyphenidyl
(TP) or propiverine (PP). To examine tau solubility in PS19 mice treated with TP or
PP, 2 μg of RAB-HS-extracted protein, 4 μg of RIPA buffer-extracted protein, and 5 μl
of FA-extracted samples from brains of 10-month-old TP- or PP-treated PS19 mice,
and non-treated control (nTC) mice were immunoblotted with 17026, a tau-speciﬁc
antibody (A). The tau protein levels are almost identical in the RAB and RIPA fractions.
In contrast, the tau protein levels are clearly different in the FA fractions, with stronger
signals following TP or PP treatment and weaker signals in the nTC PS19 mice. More-
over, slowly migrating tau bands in the FA fractions (arrow) are clearly observed in
TP- and PP-treated PS19 mice. The signal intensities of tau protein in the FA fractions
from TP- and PP-treated PS19 brains are signiﬁcantly stronger than those from nTC
PS19 brains (B). Insoluble tau proteins in the FA fractions of TP-treated and PP-treated
mice are more phosphorylated (pTau); in particular, slower migrated band (arrow) is
strongly positive for AT8 (C). M, 1N4R recombinant tau protein; RAB, reassembly buff-
er; RIPA, radioimmunoprecipitation assay; FA, formic acid. *, pb0.05.
Fig. 3. Tau phosphorylation and Tau kinesis activities. To assess the kinase activities in-
volved in tau phosphorylation, Western blot analysis is performed for active and inac-
tive kinases, including GSK3β, CDK5 and MAPKs (p38, JNK, ERK), in brain samples from
trihexyphenidyl (TP)- or propiverine (PP)-treated PS19, non-treated control (nTC)
PS19, and non-treated WT mice. Basal kinase expression in the brain is similar
among the groups; however, the activated forms of CDK5 and MAPKs (p-) are in-
creased and the inactivated form of GSK3β (pGSK3β) is decreased in TP-treated PS19
mice compared with those in nTC PS19 mice, indicating that TP treatment activates
tau kinases in PS19 mice.
333Y. Yoshiyama et al. / Neurobiology of Disease 45 (2012) 329–336activity, showed a milder pathological and biochemical deterioration
than TP. This ﬁnding agrees with the clinical observation that anticho-
linergic activity levels are proportional to the risk of dementia (Jessen
et al., 2010).
The positive correlation of microgliosis with both tau pathology and
neuronal loss, in PS19 mice treated with TP, PP or in nTCs (Figs. 2, 4)
provides a mechanism for how ACh could modify neurodegeneration.
Because microgliosis precedes tau pathology and neuronal loss, and
early administration of FK506, an immunosuppressant, attenuates
those pathologies, neuroinﬂammation and microglial activation might
be initiating processes that leads to pathology in PS19mice (Yoshiyama
et al., 2007). Thus, one possible mechanism to explain the worsening of
neuropathology, such as tau pathology and neuronal loss, is modulation
of inﬂammatory reactions by chronic administration of anticholinergics.
TP aggravated not only microgliosis in the brain, but also IL-1β expres-
sion in the spleen of PS19 mice with LPS-induced systemic inﬂamma-
tion, indicating the inﬂammation-enhancing properties of TP (Fig. 4).Recent evidence supports an anti-inﬂammatory function of ACh, and
there are some reports demonstrating that acetylcholinesterase inhibi-
tors (AChEIs) exert inhibitory inﬂuences on neuroinﬂammation and
generalized systemic inﬂammation (Pollak et al., 2005; Tyagi et al.,
2007). Peripheral administration of AChEIs, or an antisense oligonucle-
otide to AChE, signiﬁcantly attenuated IL-1β production in the hippo-
campus and blood of mice, with concomitant reduced AChE activity
(Pollak et al., 2005). Furthermore, we recently reported that donepezil,
an AChEI, ameliorated pathological changes in PS19 mice (Yoshiyama
et al., 2010). Taken together, the cholinergic nervous system might be
involved in neurodegeneration and inﬂammation. It is well-known
that neuronal inﬂammation may play an important role in the patho-
genesis of neurodegenerative disorders including AD. Acute and chronic
systemic inﬂammation may be associated with an increased risk of de-
veloping AD (Bonotis et al., 2008; Holmes et al., 2009; Tan et al.,
2007). Because early depletion of ACh is one of the pathological and bio-
chemical hallmarks of AD, a depleted ACh system in the brain might
Fig. 4. Anticholinergics enhance microglial activation in PS19 mice. Sections of the hippocampal CA3 (A–K) and CA1 (L) regions were immunoﬂuorescently double-stained with
Iba1 antibody (green) and 17026 (tau antibody, red), and sections of the CA1 region were immunohistochemically stained with CD11b (O–R) and CD68 (S–V). Low-magniﬁcation
images demonstrate more microglial activation in trihexyphenidyl (TP)-treated PS19 mice (G–I) than in propiverine (PP)-treated (D–F) or non-treated control (nTC) PS19 mice
(A–C). High-magniﬁcation images (K, L) of the hippocampus in TP-treated PS19 mice clearly demonstrate activation of microglia, which show enlarged cytoplasm with thick pro-
cesses in the CA3 region (K) and elongated rod-like cytoplasm with thick processes parallel to the nerve ﬁbers in CA1 region (L), whereas a few, small microglia with thin processes
were observed in the WT mouse brain (J). The activation of microglia was quantiﬁed by measurement of Iba1-positive area. The Iba1-positive area in TP-treated mice was signif-
icantly increased compared with that in nTC PS19 mice, both in the CA1 (M) and CA3 (N) regions. Although there is no statistical signiﬁcance of PP-treatment in Iba1-psositive area,
other activated microglial markers including CD11b and CD68 also indicate that TP-treatment (Q, U, R, V) markedly and PP-treatment (P, T) mildly activates microglia compared
with nTC (O, S). A low-magniﬁcation image stained with anti-CD68 clearly demonstrates a concentration of CD68-positive microglia in the granular neuronal cell layer (V, outlin-
ing) in the hippocampus (compare V to R). *, pb0.05, to nTC. Scale bars, 10 μm (A–L, O–Q, S–U); 100 μm (R, V).
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AD. Some studies have indicated that sustained low-grade systemic in-
ﬂammation, including elevated inﬂammation related cytokines and pro-
teins, is observed in AD (Heneka and O'Banion, 2007; Lee et al., 2009;Yaffe et al., 2004). This low-grade systemic inﬂammation in AD possibly
results from neurodegeneration in ACh system.
ACh acts through twodifferent types of receptors: nicotinic andmus-
carinic. It has been demonstrated that anti-inﬂammatory effects of ACh
Fig. 5. Anticholinergics accelerate systemic and neuronal inﬂammation induced by lipopolysaccharide (LPS) injection. Three-month-old PS19 mice fed powdered food mixed with
trihexyphenidyl (TP) (A, D, G), propiverine (PP) (B, E, H) or no drug (nTC) (C, F, I) were peritoneally injected with 1 mg/kg LPS twice a week for 1 month, and then sacriﬁced at
4 months old. IL-1β expression in the spleen (A–C) is increased in the TT-treated mice (A) compared with the nTC mice (C). Similarly, neuronal IL-1β expression in the CA3 region
(D–F) in the TT-treated mice is enhanced (D) in accordance with the microglial activation detected with Iba1 antibody (G–I). Scale bars, 20 μm.
335Y. Yoshiyama et al. / Neurobiology of Disease 45 (2012) 329–336are mainly regulated by nicotinic ACh receptors in macrophages (Wang
et al., 2003) and microglia (De Simone et al., 2005). Because most clini-
cally used anticholinergics are classiﬁed as anti-muscarinic agents, anti-
cholinergics may not exert their inﬂammation-enhancing effects by
directly suppressing nicotinic receptors on immunocompetent cells. In-
terestingly, AChEIs suppresses TNF production in the blood and spleen
following LPS-induced systemic inﬂammation in mice (Pavlov et al.,
2009). Meanwhile, the suppressive effect on blood TNF was reversed
by surgical transection of the cervical vagus nerve or pre-treatment
with atropine sulfate, a blood–brain barrier-permeable muscarinic re-
ceptor antagonist. However, atropine methyl nitrate, a blood–brain bar-
rier-impermeable muscarinic receptor antagonist, produced no effect. A
highly selective, centrally acting AChEI, huperzine A, signiﬁcantly re-
duced blood TNF levels (Pavlov et al., 2009).Moreover, muscarine injec-
tion into the lateral ventricle reduced the levels of inﬂammatory
mediators in both brain and spleen in experimental intracerebral hem-
orrhage rats (Lee et al., 2010). These data indicate a centrally controlled
muscarinic receptor-dependent anti-inﬂammatory mechanism for both
the central nervous system and peripheral systemic organs.
Anticholinergic drugs not only impair cognitive function by de-
creased ACh neurotransmission, but also accelerate neurodegeneration
by suppressing ACh-dependent anti-inﬂammatory system. Anticholin-
ergics should be less readily prescribed, to reduce the risk of dementia.
Moreover drugs targeting the ACh-dependent anti-inﬂammatory sys-
tem might be candidates for reducing the risk of dementia.
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